| Effects of interferons alpha/beta on the proliferation of human micro- and macrovascular endothelial cells. Erdmann J., Vitale G., van Koetsveld P.M., Croze E., Sprij-Mooij D.M., Hofland L.J., van Eijck C.H.
J. Interferon Cytokine Res. 31:451-458(2011) · Mapped (4) |
| Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Vitale G., van Eijck C.H., van Koetsveld Ing P.M., Erdmann J.I., Speel E.J., van der Wansem Ing K., Mooij D.M., Colao A., Lombardi G., Croze E. et al.
Ann. Surg. 246:259-268(2007) · Mapped (4) |
| Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Wang Y.X., da Cunha V., Vincelette J., White K., Velichko S., Xu Y., Gross C., Fitch R.M., Halks-Miller M., Larsen B.R. et al.
Am. J. Physiol. Heart Circ. Physiol. 293:H69-76(2007) · Mapped (7) |
| SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. Kumar K.G., Tang W., Ravindranath A.K., Clark W.A., Croze E., Fuchs S.Y.
EMBO J. 22:5480-5490(2003) · UniProtKB (1) · Mapped (13) |
| STAT3 activation by type I interferons is dependent on specific tyrosines located in the cytoplasmic domain of interferon receptor chain 2c. Activation of multiple STATS proceeds through the redundant usage of two tyrosine residues. Velichko S., Wagner T.C., Turkson J., Jove R., Croze E.
J. Biol. Chem. 277:35635-35641(2002) · UniProtKB (1) · Mapped (8) |
| Interferon signaling is dependent on specific tyrosines located within the intracellular domain of IFNAR2c. Expression of IFNAR2c tyrosine mutants in U5A cells. Wagner T.C., Velichko S., Vogel D., Rani M.R., Leung S., Ransohoff R.M., Stark G.R., Perez H.D., Croze E.
J. Biol. Chem. 277:1493-1499(2002) · UniProtKB (1) |
| Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Russell-Harde D., Wagner T.C., Perez H.D., Croze E.
Biochem. Biophys. Res. Commun. 255:539-544(1999) · UniProtKB (2) |
| The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action. Pfeffer L.M., Basu L., Pfeffer S.R., Yang C.H., Murti A., Russell-Harde D., Croze E.
J. Biol. Chem. 272:11002-11005(1997) · Mapped (5) |
